56results about How to "High neutralizing activity" patented technology

The invention relates to a coxsackie virus A16 type virus-like particle vaccine. The inventor fortuitously finds that proteins which have better spatial configurations and are suitably cut can be obtained by expressing P1 protein of CVA16 and 3CD protein of CVA16 by infecting insect cells with rhabdovirus. The proteins can be automatically assembled into a virus-like particle which has high immunogenicity.

The invention discloses a neutralizing nano antibody for resisting novel coronavirus SARS-CoV-2 and application thereof, and belongs to the technical field of biological medicine. Variable regions of the neutralizing nano antibody are provided with three complementary determining regions CDR1, CDR2 and CDR3; and the neutralizing nano antibody is any one of (a1)-(a6). The neutralizing nano antibody for resisting novel coronavirus SARS-CoV-2 provided by the invention can be effectively combined with an RBD antigen, can effectively compete with human ACE2 protein to be combined with the RBD antigen after being fused with a human IgGFc tag, has high neutralizing activity on SARS-CoV-2 pseudotype virus, and has important scientific significance and application prospects for prevention and clinical treatment of diseases caused by the novel coronavirus SARS-CoV-2 and research and development of diagnostic reagents.

The invention relates to the field of biological medicine, and discloses a fully human monoclonal neutralizing antibody for resisting novel coronavirus and application of the fully human monoclonal neutralizing antibody. B-type lymphocytes are screened from blood of a new coronal pneumonia rehabilitation patient, and the affinity constant of the obtained antibody and a virus receptor binding domain (RBD) is 1.19 nM. X-ray crystal diffraction is used for analyzing the three-dimensional structure of the antibody and RBD compound, it is found that the binding epitope of the antibody and the binding epitope of a host cell receptor (ACE2) are highly overlapped, binding of the RBD and the ACE2 can be competitively blocked, and infection of the RBD and the ACE2 is inhibited. The antibody can cope with certain genetic mutations of viruses, the half effective concentration of the antibody for blocking pseudoviruses (accumulated B.1. 1.7 mutant strain genes and D614G) from infecting host cells is 0.57 ng/mL, and the antibody has the advantages of safety, high efficiency and broad spectrum, and is expected to be used as a neutralizing antibody drug for diagnosing, treating and preventing new coronal pneumonia.

The invention discloses neutralizing monoclonal antibodies for resisting the H7N9 influenza virus and particularly discloses two monoclonal antibodies aiming at the H7N9 influenza virus. The antibodies has evident combining activity to H7N9 influenza virus antigens.

The invention discloses a fully-human neutralizing antibody of anti-respiratory syncytial virus fusion protein and application of the fully-human neutralizing antibody. Specifically, the invention discloses a fully human monoclonal antibody 4F1 aiming at respiratory syncytial virus fusion protein (F protein) and pre-fusion F protein (preF protein), a nucleic acid sequence for encoding an antibodyand an antibody fragment, and a preparation method of the nucleic acid sequence. In-vitro and in-vivo experiments prove that the 4F1 antibody can effectively prevent and control RSV infection, has lowimmunogenicity for a human body, can avoid antibody-mediated immunological rejection of human anti-mouse and other species sources, and can be clinically used for preventing and treating respiratorysyncytial virus infection.

The invention relates to the field of biological medicine, and discloses a fully human monoclonal antibody for resisting novel coronavirus and application of the fully human monoclonal antibody. An SARS-CoV2 receptor binding domain (RBD) is used as a probe, flow cytometry is used for screening B lymphocytes of a new coronary pneumonia rehabilitation patient, and the affinity constant of the prepared monoclonal antibody and the RBD is 4.03 nM. X-ray crystal diffraction is used for analyzing the three-dimensional structure of the antibody and RBD compound to find that binding epitopes of the antibody and a host cell receptor (ACE2) are overlapped, binding of the RBD and the ACE2 can be competitively blocked, the virus is prevented from infecting host cells, some genetic mutations of the new coronavirus can be coped with. The median effective concentration (IC50) for blocking pseudoviruses (accumulated B.1. 1.7 mutant strain genes and D614G) from infecting host cells is 0.12 ng/mL, and the application prospect of diagnosing, treating and preventing the new coronal pneumonia is achieved.

Provided are an anti-human NGF antibody which is reduced in the influence on fetuses and the risk of adverse side effects including thrombosis while keeping a high neutralizing activity, and which has excellent safety, or an antigen-binding fragment thereof; and a means, utilizing the antibody or an antigen-binding fragment thereof , for preventing or treating various diseases for which human NGF is involved in the development of a disease state. An Fab' fragment of an anti-human NGF antibody comprises a heavy-chain variable region comprising the amino acid sequence represented by SEQ ID NO: 6 and a light-chain variable region comprising the amino acid sequence represented by SEQ ID NO: 4.

The invention adopts a monoclonal antibody 5D9 with neutralization activity to both PRRSV-I and PRRSV-II viruses to prepare an immunoenhancer. When a formed immune complex is combined with an adjuvantto immunize mice, T cells secreted by IFN-gamma are significantly increased, suggesting that combined immunization of the PRRSV specific antibody 5D9 and the normal oil in water adjuvant can enhanceCTL reaction in the process of inactivating virus immunity. Animal tests show that the immune protection rate of the immune complex prepared by the method can achieve a higher protection effect than that of a vaccine and a commercialized attenuated vaccine prepared only with a commercial adjuvant ISA 206.

The invention provides an enterovirus 71 (EV71) monoclonal antibody and an application thereof. The monoclonal antibody is derived from an EV71 hybrid tumor cell strain, which has a preservation number of CGMCC (China General Microbiological Culture Collection) No.5330. The monoclonal antibody and related reagents thereof have important significance in promoting the treatment and research of severe cases and death cases caused by EV71 in China, and have extremely important value in further promoting clinical research, epidemic development and passive treatment of EV71.

The invention relates to an anti-SARS-CoV-2 single-chain antibody, and a preparation method and application thereof. The complementary determining region of the anti-SARS-CoV-2 single-chain antibody comprises a CDR1 and a CDR3, wherein the CDR1 comprises an amino acid sequence as shown in SEQ ID NO.1 or SEQ ID NO.2, and the CDR3 comprises an amino acid sequence as shown in SEQ ID NO.3 or SEQ ID NO.4. The anti-SARS-CoV-2 single-chain antibody has high affinity, can be efficiently combined with SARS-CoV-2, is unlikely to dissociate, has a high virus neutralizing activity, can be efficiently expressed in a prokaryotic system, has a standard and controllable expression process, can greatly reduce the production cost, is small in molecular weight, is stable in physicochemical properties and good in heat resistance, can greatly reduce the transportation cost as a prevention and treatment drug, and has an important application value in the field of SARS-CoV-2 prevention and treatment.

A monoclonal antibody, which recognizes at least two amino acids among amino acids located at position 69, position 79, position 81 and position 102 of human midkine, has been found to have excellent reactivity with and excellent neutralizing activity against human midkine. Moreover, the activity of suppressing the proliferation of tumor has been observed in the antibody having excellent neutralizing activity. The use of the antibody of the present invention makes it possible to treat cancer effectively and to detect or purify midkine efficiently.

The invention provides a construction body (including a multivalent nano antibody and a nano antibody fusion protein) of a nano antibody R14 based on specific binding SARS-CoV-2RBD, a related product thereof and an application of the construction body. The construction body (including multivalent nano-antibody and nano-antibody fusion protein) of the nano-antibody R14 based on the specific binding SARS-CoV-2RBD can effectively inhibit SARS-CoV-2 infection and variant strain infection thereof, can be dosed by atomization, can directly reach the lung, takes effect quickly, is long in half-life period, and can be used for preparing the nano-antibody R14 of the SARS-CoV-2RBD. And a more effective treatment strategy is provided for clinically preventing or treating infection of the new coronavirus and the variant thereof.

The invention discloses an adjuvant of a novel coronavirus COVID-19 vaccine and a developed bivalent vaccine which contains a novel coronavirus epidemic HuB strain and a South African mutant strain B.1.351 antigen. The adjuvant disclosed by the invention has the advantages of being more suitable for a stable sodium acetate buffer solution system of a COVID-19 vaccine protein, and high in neutralizing antibody and cellular immune level. On the basis, the bivalent COVID-19 vaccine invented by the invention can have a good protection effect on infection of the novel coronaviruses, especially the HuB strain, the South African mutant strain and a Delta mutant strain.

The invention discloses a neutralizing monoclonal antibody capable of resisting an enterovirus D68 in a broad-spectrum way. Particularly, the invention discloses two strains of monoclonal antibodies which aim at the enterovirus D68. The monoclonal antibodies have obvious binding and neutralizing activity for the enterovirus D68.

The invention relates to an antibody composition containing a monoclonal antibody specifically bound to an S protein receptor binding domain of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) and a monoclonal antibody specifically bound to an S protein N-terminal structural domain of the SARS-CoV-2. Compared to the monoclonal antibodies separately used, the antibody composition is significantly improved in the aspect of the neutralizing activity on novel coronavirus infected cells, the neutralizing activity is respectively increased to 6.4 times of that of an anti-S protein receptor binding domain and 3.8 times of that of an anti-S protein N-terminal structural domain, and the antibody composition has a remarkable synergistic effect. The invention further relates to application of the antibody composition to preparation of COVID-19 treatment and/or prevention drugs. The antibody composition can be prepared on a large scale by stable engineered strains and an industrial pharmaceutical method, and has a huge industrial prospect.

The invention provides a construction body (including a multivalent nano antibody and nano antibody fusion protein) of a nano antibody S43 based on specific binding of SARS-CoV-2RBD, and a related product and application thereof. The construction body (including multivalent nano-antibody and nano-antibody fusion protein) of the nano-antibody S43 based on specific binding of SARS-CoV-2RBD can effectively inhibit SARS-CoV-2 infection and variant strain infection thereof, can be dosed in an atomized manner, can directly reach the lung, takes effect quickly, is long in half-life period, and can be used for preparing the nano-antibody S43 with the specific binding of SARS-CoV-2RBD. And a more effective treatment strategy is provided for clinically preventing or treating infection of the new coronavirus and the variant thereof.

The invention discloses a whole-humanized neutralizing antibody resisting an H3N2 influenza virus and application of the hole-human neutralizing antibody. Particularly, the invention discloses a whole-humanized monoclonal antibody for the H3N2 influenza virus. The antibody can bind influenza virus hemagglutinin (HA) with a native conformation, can prevent the H3N2 subtype influenza virus from infecting susceptible cells, has lower immunogenicity for human bodies, can avoid medicated immune rejection response of antibodies derived from other specifies such as a human anti-mouse antibody, and has potential values of preventing and treating H3N2 subtype influenza virus infection clinically.

The invention relates to a human neutralizing antibody or an antigen binding fragment thereof and application thereof, the human neutralizing antibody or the antigen binding fragment comprises a heavy chain variable region and/or a light chain variable region, the heavy chain variable region comprises amino acid sequences: (I) HCDR1, HCDR2 and HCDR3 respectively shown as SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3; or (II) HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO: 11, 12 and 13 respectively, or (II) HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO: 12 and 13 respectively; or (III) HCDR1, HCDR2 and HCDR3 of which the amino acid sequences are respectively shown as SEQ ID NO: 21, 22 and 23; the light chain variable region comprises amino acid sequences: (I) an LCDR1, an LCDR2 and an LCDR3 respectively shown as SEQ ID NO: 4, 5 and 6; or (II) an LCDR1, an LCDR2 and an LCDR3 as shown in SEQ ID NO: 14, 15 and 16 respectively, or (II) an LCDR1, an LCDR2 and an LCDR3 as shown in SEQ ID NO: 16 respectively; or (III) LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO: 24, 35 and 26, respectively, as shown in SEQ ID NO: 16, SEQ ID NO: 24, SEQ ID NO: 35 and SEQ ID NO: 26. The neutralizing antibody YB9-258, the neutralizing antibody YB13-292 and the neutralizing antibody YB13-208 disclosed by the invention can be used for effectively inhibiting SARS-CoV-2 pseudovirus infection, and also has relatively good neutralizing activity on an SARS-CoV-2 true virus.